Royalty Pharma plc
RPRX
Rank in Stocks
#892
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Share Price
$60.39
Last synced: 2026-10-19
Market Cap
$26.89B
Change (1 day)
-0.93%
Change (1 year)
64.87%
Country
US
Trade Royalty Pharma plc (RPRX)
Category
Healthcare
P/E ratio for Royalty Pharma plc (RPRX)
P/E ratio as of October 2026 TTM: 24.47
According to Royalty Pharma plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 24.47. At the end of 2023 the company had a P/E ratio of 11.08.
P/E ratio history for Royalty Pharma plc from 2015 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 24.47 | 84.84% |
| 2024 | 13.24 | 19.55% |
| 2023 | 11.08 | -97.26% |
| 2022 | 404.10 | 1,415.05% |
| 2021 | 26.67 | 33.87% |
| 2020 | 19.92 | 196.88% |
| 2019 | 6.71 | -41.34% |
| 2018 | 11.44 | -12.17% |
| 2017 | 13.03 | -72.71% |
| 2016 | 47.73 | 2.74% |
| 2015 | 46.46 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 33.58 | 37.23% |
HK
|
|
| 223.52 | 813.33% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.